Patents by Inventor Jiajian Liu
Jiajian Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11912763Abstract: Provided is an antibody targeting CLDN18.2. The antibody targeting CLDN118.2 comprises VL and/or VH; the VL comprises the following CDR sequences: a VL CDR1 amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; a VL CDR2 amino acid sequence as shown in SEQ ID NO: 13; and a VL CDR3 amino acid sequence as shown in SEQ ID NO: 14; and the VH comprises the following CDR sequences; a VH CDR1 amino acid sequence as shown in SEQ ID NO: 15; a VH CDR2 amino acid sequence as shown in SEQ ID NO: 16; and a VH CDR3 amino acid sequence as shown in SEQ ID NO: 17. Further disclosed are a bispecific antibody targeting CLDN18.2, a conjugates of the antibody, a CAR molecule targeting CLDN18.2 and a cell comprising same, and applications thereof.Type: GrantFiled: June 6, 2019Date of Patent: February 27, 2024Assignee: L & L BIOPHARMA CO., LTD.Inventor: Jiajian Liu
-
Publication number: 20230106247Abstract: Disclosed is a SIRP?-targeting antibody or an antigen-binding fragment thereof, comprising a light chain variable region and/or a heavy chain variable region. The antibody or the antigen-binding fragment thereof binds to human SIRP?-V1 and human SIRP?-V2, but weakly or does not bind to human SIRP? and SIRP?, does not bind to human T cells, and has the function of blocking the binding of SIRP? to CD47. Further disclosed are a bispecific antibody comprising same, a method for preparing the antibody or the antigen-binding fragment thereof and an application thereof. The unique properties of the disclosed antibody or the antigen-binding fragment thereof enable same to be more suitable for the development of drugs for an antibody or antigen-binding fragment against a human SIRP? target. As a candidate drug, same can be administered alone or in combination, providing a new or even better choice for the combined immunotherapy of tumors.Type: ApplicationFiled: March 17, 2021Publication date: April 6, 2023Inventor: Jiajian LIU
-
Publication number: 20220340657Abstract: Disclosed is a LAG-3 binding protein, comprising a light chain variable region and/or a heavy chain variable region. The light chain variable region comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO: 5, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 6, and/or a CDR3 having an amino acid sequence as shown in SEQ ID NO: 7. The heavy chain variable region comprises a CDR1 having an amino acid sequence as shown in SEQ ID NO: 8, a CDR2 having an amino acid sequence as shown in SEQ ID NO: 9, and/or a CDR3 having an amino acid sequence as shown in SEQ ID NO: 10. Also disclosed are a bispecific antibody targeting LAG-3 and use thereof. The LAG-3 binding protein and bispecific antibody above can effectively block the binding of LAG-3 to MHC II and activate T cells.Type: ApplicationFiled: June 11, 2020Publication date: October 27, 2022Inventor: Jiajian LIU
-
Publication number: 20210269521Abstract: The present invention provides a bispecific antibody and a use thereof. The bispecific antibody comprises a first protein functional zone and a second protein functional zone. TIM-3 full-length antibody of targeting TIM-3 corresponding to the targeting TIM-3 in the first protein functional zone has a low binding activity with Macaca TIM-3, has strong binding activity with Marmoset and human TIM-3, and can activate the killing effect of a human NK cell on the tumor cell. The bispecific antibody reserves the activity of a single TIM-3 antibody of activating PBMC(NK) to kill the tumor cell while reserving the original activity of the other protein functional zone, and can achieve the same activity of being combined with two molecules or better activate the activity of a T lymphocyte.Type: ApplicationFiled: June 28, 2019Publication date: September 2, 2021Applicant: L&L BIOPHARMA CO., LTD.Inventor: Jiajian LIU
-
Publication number: 20210230272Abstract: Provided is an antibody targeting CLDN18.2. The antibody targeting CLDN18.2 comprises VL and/or VH; the VL comprises the following CDR sequences: a VL CDR amino acid sequence as shown in SEQ ID NO: 11 or SEQ ID NO: 12; a VL CDR2 amino acid sequence as shown in SEQ ID NO: 13; and a VL CDR3 amino acid sequence as shown in SEQ ID NO: 14; and the VH comprises the following CDR sequences; a VH CDR1 amino acid sequence as shown in SEQ ID NO: 15; a VH CDR2 amino acid sequence as shown in SEQ ID NO: 16; and a VH CDR3 amino acid sequence as shown in SEQ ID NO: 17. Further disclosed are a bispecific antibody targeting CLDN18.2, a conjugates of the antibody, a CAR molecule targeting CLDN18.2 and a cell comprising same, and applications thereof.Type: ApplicationFiled: June 6, 2019Publication date: July 29, 2021Applicant: L&L BIOPHARMA CO., LTD.Inventor: Jiajian LIU
-
Patent number: 10543284Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.Type: GrantFiled: April 7, 2016Date of Patent: January 28, 2020Assignees: Suzhou Suncadia Biopharmaceuticals Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jiajian Liu, Lianshan Zhang, Weikang Tao, Yayuan Fu, Ling Zhang, Dong Ma, Dongbing Cui, Yali Wang, Jianyan Xu, Jindong Liang, Ying Zhang, Guiyang Jiang, Junzhuan Qiu, Ziyong Sun, Jiping Zha, Jingping Wei
-
Patent number: 10449250Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).Type: GrantFiled: February 16, 2016Date of Patent: October 22, 2019Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jiajian Liu, Yayuan Fu, Haoying Zhang, Yifang Wang, Zhen Zhang, Ling Zhang, Dongbing Cui, Lianshan Zhang, Weikang Tao
-
Publication number: 20190315886Abstract: Provided are a thrombin antibody, an antigen-binding fragment and a pharmaceutical use thereof. Further provided are a chimeric antibody and a humanized antibody comprising a thrombin antibody CDR region, and a pharmaceutical composition comprising the thrombin antibody and the antigen-binding fragment thereof, as well as the use thereof as an anticoagulant drug. In particular, provided is a use of the humanized thrombin antibody in preparing a drug for treating a thrombin-mediated disease or condition.Type: ApplicationFiled: February 3, 2017Publication date: October 17, 2019Inventors: Hua YING, Jiajian LIU, Yayuan FU, Ling ZHANG, Haoying ZHANG, Jiakang SUN, Lianshan ZHANG, Weikang TAO, Piaoyang SUN, Qiyue HU
-
Patent number: 10351820Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.Type: GrantFiled: March 13, 2017Date of Patent: July 16, 2019Assignee: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain Andre Bonnet
-
Patent number: 10233421Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.Type: GrantFiled: March 13, 2017Date of Patent: March 19, 2019Assignee: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain Andre Bonnet
-
Patent number: 10050552Abstract: A high-frequency isolation alternating/direct current conversion circuit and a control method thereof are disclosed. The conversion circuit includes an alternating current source, a direct current source, a resonant capacitor, a high-voltage energy-storage filter, a high-frequency inverter bridge, a drive circuit, a resonant inductor, a high-frequency isolation transformer, a direct current side synchronous switch, a control circuit, and the like. The conversion circuit is made to be switched between two working modes, a rectification mode and an inversion mode by using a preset direct current source reference voltage as a reference, according to an external voltage reference, and by using different turn-on working modes of the high-frequency inverter bridge.Type: GrantFiled: August 30, 2017Date of Patent: August 14, 2018Assignee: SHENZHEN BOYN ELECTRIC CO., LTD.Inventors: Lunquan Li, Jiajian Liu, Sha Yan
-
Publication number: 20180127723Abstract: The present invention provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3? (GSK-3B) enzyme activity.Type: ApplicationFiled: December 18, 2017Publication date: May 10, 2018Applicant: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu
-
Publication number: 20180110875Abstract: Provided are an anti-c-Met antibody or an antigen binding fragment thereof, and an anti-c-Met antibody-cytotoxic drug conjugate, wherein the antibody or antigen binding fragment thereof is a chimeric antibody or a humanized antibody. Also provided are pharmaceutical compositions containing the humanized anti-c-Met antibody or antigen binding fragment thereof, the antibody-cytotoxic drug conjugate, or pharmaceutically acceptable salts or solvents thereof, that are used in the treatment of cancer.Type: ApplicationFiled: April 7, 2016Publication date: April 26, 2018Inventors: Jiajian LIU, Lianshan ZHANG, Weikang TAO, Yayuan FU, Ling ZHANG, Dong MA, Dongbing CUI, Yali WANG, Jianyan XU, Jindong LIANG, Ying ZHANG, Guiyang JIANG, Junzhuan QIU, Ziyong SUN, Jiping ZHA, Jingping WEI
-
Publication number: 20180099046Abstract: Provided is a humanized antibody and chimeric antibody that specifically binds human sclerostin. The antibodies can be used for treating human bone metabolism related diseases such as osteoporosis (OP).Type: ApplicationFiled: February 16, 2016Publication date: April 12, 2018Applicants: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Jiajian LIU, Yayuan FU, Haoying ZHANG, Yifang WANG, Zhen ZHANG, Ling ZHANG, Dongbing CUI, Lianshan ZHANG, Weikang TAO
-
Patent number: 9862765Abstract: Provided is an antibody capable of specially recognizing IL-17A and binding to IL-17A. The antibody can be used for treating inflammation and autoimmune diseases caused by elevated expression of interleukin-17A, such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis.Type: GrantFiled: October 27, 2014Date of Patent: January 9, 2018Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.Inventors: Lianshan Zhang, Jiajian Liu, Guoqing Cao, Piaoyang Sun
-
Publication number: 20170366099Abstract: A high-frequency isolation alternating/direct current conversion circuit and a control method thereof are disclosed. The conversion circuit includes an alternating current source, a direct current source, a resonant capacitor, a high-voltage energy-storage filter, a high-frequency inverter bridge, a drive circuit, a resonant inductor, a high-frequency isolation transformer, a direct current side synchronous switch, a control circuit, and the like. The conversion circuit is made to be switched between two working modes, a rectification mode and an inversion mode by using a preset direct current source reference voltage as a reference, according to an external voltage reference, and by using different turn-on working modes of the high-frequency inverter bridge.Type: ApplicationFiled: August 30, 2017Publication date: December 21, 2017Inventors: Lunquan LI, Jiajian LIU, Sha YAN
-
Patent number: 9845460Abstract: The present invention is provides a method for treating human pluripotent cells. In particular, the methods of the invention are directed to the treatment of human pluripotent cells, whereby the human pluripotent cells can be efficiently expanded in culture and differentiated by treating the pluripotent cells with an inhibitor of glycogen synthase kinase 3? (GSK-3B) enzyme activity.Type: GrantFiled: November 20, 2013Date of Patent: December 19, 2017Assignee: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu
-
Publication number: 20170183625Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain Andre Bonnet
-
Publication number: 20170183624Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.Type: ApplicationFiled: March 13, 2017Publication date: June 29, 2017Applicant: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain Andre Bonnet
-
Patent number: 9593305Abstract: The present invention is directed to methods to differentiate pluripotent stem cells. In particular, the present invention is directed to methods and compositions to differentiate pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage comprising culturing the pluripotent stem cells in medium comprising a sufficient amount of GDF-8 to cause the differentiation of the pluripotent stem cells into cells expressing markers characteristic of the definitive endoderm lineage.Type: GrantFiled: March 29, 2012Date of Patent: March 14, 2017Assignee: Janssen Biotech, Inc.Inventors: Janet Davis, Jiajian Liu, Christine Parmenter, Pascal Ghislain André Bonnet